Aminopeptidase: A Comprehensive Reference
1. Identity, Nomenclature, and Chemical Classification
Aminopeptidases are a class of hydrolytic enzymes formally designated under Enzyme Commission number EC 3.4.11. Aminopeptidases (EC 3.4.11.) belong to the exoprotease family, which can catalyze the cleavage of peptide bonds connecting the N-terminal amino acid to the penultimate residue in a protein. More precisely, an aminopeptidase is an enzyme that catalyzes the cleavage of amino acids from the amino terminus (N-terminus) of protein or peptide substrates. Synonyms of aminopeptidase include "aminopolypeptidase" and "peptidase, amino-."
Among the best-characterized members of this class is Aminopeptidase N (APN), also known as CD13, microsomal aminopeptidase, aminopeptidase M, alanine aminopeptidase, particle-bound aminopeptidase, p146, p161 or gp150; a Zn2+-dependent membrane-bound ectopeptidase with EC number 3.4.11.2. A widely studied dietary-supplement-relevant form is leucyl aminopeptidase (LAP), bearing EC number 3.4.11.1. The FDA GRAS notification system recognizes a specific form with EC number 3.4.11.15 and CAS number 114796-97-3.
Classification systems. Aminopeptidases can be classified into leucine, lysine, methionine, and proline aminopeptidases by hydrolyzed N-terminal residues; metallo-, serine-, and cysteine-aminopeptidases by reaction mechanisms; dipeptide and tripeptide enzymes by the number of amino acid residues released; or acidic, neutral, and basic aminopeptidases. Aminopeptidases are further classified by: (1) the number of amino acids cleaved from the amino terminus; (2) the location of the aminopeptidase in the cell; (3) susceptibility to inhibition by bestatin; (4) metal ion content; (5) pH at which maximal activity is observed; and (6) the relative efficiency with which residues are removed.
Regarding catalytic mechanism, the most industrially and clinically prominent aminopeptidases are metalloenzymes. A well-characterized aminopeptidase is a 66 kDa protein identified as a zinc metalloenzyme (one atom of zinc per molecule of enzyme). The primary sequence of the enzyme contains a putative zinc binding motif HEXXH. Other families utilize different catalytic residues: cysteine aminopeptidases rely on a cysteine amino acid to perform catalysis; these enzymes are part of a broader group of cysteine proteases that carve up proteins by using a nucleophilic cysteine thiol along with one or two other catalytic amino acids in a diad or triad. The triad typically consists of cysteine, histidine, and aspartate amino acids, where the cysteine acts as a nucleophile, the histidine acts as a chemical base, and the aspartate stabilizes the histidine.
Distribution. Aminopeptidases are widely distributed throughout the animal and plant kingdoms and are found in many subcellular organelles, in cytosol, and as membrane components. Endogenously in humans, Aminopeptidase N (AP-N or CD13) has been extensively characterized for its broad substrate specificity and its presence in various tissues such as the brush border membranes of the kidney, small intestine, and placenta. Human membrane-bound aminopeptidase P is widely expressed, with expression detected in kidney, lung, heart, placenta, liver, small intestine, and colon.
2. Natural Sources and Production
Aminopeptidases are produced by a broad range of organisms including bacteria, fungi, plants, and animals. In the industrial and supplement context, microbial sources dominate. Microorganisms are preferred sources of industrial enzymes as they are economic, effective, and have a controllable enzyme reaction mechanism. Most accepted patents on aminopeptidases are from Aspergillus strains.
- Aspergillus oryzae and Aspergillus sojae: In the food industry, aminopeptidases from Aspergillus oryzae and Aspergillus sojae are utilized for debittering protein hydrolysates, including those used in soy sauce and miso production. Leucine aminopeptidase (LAP) from Aspergillus species has been found to be thermostable.
- Aspergillus niger: This species is used to derive endopeptidases relevant to food-grade gluten-degrading enzyme preparations.
- Aspergillus clavatus: The source for one FDA-reviewed aminopeptidase preparation is Aspergillus clavatus, a species found in soils and animal manure.
- Lichtheimia ramosa: The food enzyme leucyl aminopeptidase (EC 3.4.11.1) is also produced with the non-genetically modified Lichtheimia ramosa strain AE-PER by Amano Enzyme Inc.
- Lactic acid bacteria (LAB): Several Lactobacillus species harbor clinically studied aminopeptidases, particularly in the context of fermented food production and gluten hydrolysis research.
- Bovine skeletal muscle: An aminopeptidase was purified from bovine skeletal muscle by ammonium sulfate fractionation and by successive chromatographic methods. This serves as both a model for basic research and a source for some animal-derived preparations.
Common commercial trade names for aminopeptidase-containing industrial enzyme preparations include: Flavourzyme (Novo Nordisk), Debitrase (Imperial Biotechnology Ltd.), Corolase (Rohm GmbH), and Pronase (Calbiochem).
3. Historical and Traditional Use
Discovery history. The discovery and characterization of aminopeptidases date back to the early 20th century. The term "aminopeptidase" was first introduced in 1929 by Linderstrøm-Lang and Sato to describe enzymes that cleave amino acids from the N-terminus of peptides. In the 1950s and 1960s, the discovery of leucine aminopeptidase (LAP) and aminopeptidase N (APN) marked important milestones in the field; LAP was found to be crucial for protein digestion, while APN was recognized for its role in the regulation of peptide-mediated effects.
Traditional fermented foods. While ancient cultures did not isolate aminopeptidases as discrete entities, they unknowingly exploited aminopeptidase activity in the production of fermented protein-rich foods for centuries. The production of miso and soy sauce in East Asian cultures is a primary example. Koji molds are used for the preparation of soy sauce, miso (fermented soybean paste), and other natural seasonings containing protein hydrolysates. Soy sauce is produced via a koji preparation step and a fermentation step; the starting materials are hydrolyzed by enzymes produced by a koji mold—a filamentous fungus belonging to the genus Aspergillus. For improving the taste of the soy sauce, it is important to increase the amount of free amino acids in these steps. Research has confirmed that during soy sauce fermentation specifically, leucine aminopeptidase plays a positive role during the early stage of soybean mash fermentation, with leucine aminopeptidase A being a dominant proteolytic enzyme during the later period of fermentation.
Traditional cheese-making. Aminopeptidases also play a crucial role in cheese ripening by participating in the proteolysis of milk proteins; this enzymatic action contributes significantly to the development of the cheese's flavor and texture, making aminopeptidases essential in the cheese-making process. Traditional artisan cheesemaking across European cultures has relied on these endogenous enzymatic processes for centuries.
Bestatin (Ubenimex). A historically significant pharmacological application involves the aminopeptidase inhibitor bestatin. Bestatin was screened as an inhibitor of aminopeptidase B in 1976. Bestatin was primarily marketed in 1987 in Japan as an anticancer drug and serves as the only marketed inhibitor of Aminopeptidase N (APN/CD13) to treat leukemia to date. This pharmacological history, though involving an inhibitor rather than the enzyme itself, reflects the longstanding clinical interest in aminopeptidase biology.
4. Key Constituents and Active Compounds
Because aminopeptidase is itself an enzyme (a protein), its "active constituent" is the protein molecule itself, defined by its catalytic mechanism, metal cofactor requirements, and substrate specificity. There is no secondary phytochemical profile as with botanical extracts.
4.1 Zinc Metalloaminopeptidases
The most broadly expressed and industrially relevant aminopeptidases are zinc metalloenzymes. In the brain renin-angiotensin system, Aminopeptidase A (APA) and Aminopeptidase N (APN) are two membrane-bound zinc metalloproteases involved in the metabolism of angiotensin II and angiotensin III respectively. Aminopeptidase A (APA) (EC 3.4.11.7) is a membrane-bound zinc metalloprotease that hydrolyzes in vivo the N-terminal aspartate of AngII (Ang 1–8) to generate AngIII (Ang 2–8).
4.2 Leucyl Aminopeptidase (LAP, EC 3.4.11.1)
This is the isoform most commonly found in commercial food enzyme and supplement preparations. In all intended food manufacturing processes, leucyl aminopeptidase hydrolyzes peptide bonds in proteins and releases free amino acids. This isoform is thermostable and catalytically active across a range of conditions suitable for food processing.
4.3 Serine-Dependent Aminopeptidases
Some aminopeptidases operate via serine-based catalysis rather than metal coordination. Enzymatic activity in certain aminopeptidases is enhanced by addition of specific anions, while activity is strongly inhibited by bestatin, PMSF, and puromycin, suggesting a serine protease mechanism.
4.4 Proline-Specific Aminopeptidases
This biochemically distinct subclass has attracted special attention for applications in gluten hydrolysis and peptide synthesis. From the viewpoint of biotechnology, proline aminopeptidases might be a perfect tool for synthesizing peptides containing proline by catalyzing aminolysis reactions. Proline-containing peptides are reported to have nutraceutical properties; studies on prolyl hydroxyproline (Pro-Hyp) have demonstrated that they can stimulate the growth of fibroblasts from mouse skin. This evidence is, however, preclinical (in vitro and animal).
5. Mechanisms of Action
5.1 Exopeptidase Proteolysis
The defining mechanism of all aminopeptidases is sequential N-terminal cleavage. Aminopeptidases catalyze the process of removal of N-terminal amino acids of target substrates by sequential cleavage of one amino acid residue at a time. This distinguishes them from endoproteases (which cleave internal peptide bonds) and carboxypeptidases (which act at the C-terminus). In the gastrointestinal tract, aminopeptidases in the gastrointestinal tract, such as APN and APA, are essential for the digestion of dietary proteins; they facilitate the absorption and utilization of amino acids by cleaving them from the N-terminus of peptides.
5.2 Regulation of Vasoactive Peptides
A distinct and physiologically critical mechanism involves aminopeptidase-mediated processing of angiotensin peptides. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. The hyperactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and maintenance of hypertension in several experimental and genetic hypertension animal models. Aminopeptidase A (APA) is involved in the conversion of angiotensin II (AngII) to AngIII in the murine brain, and AngIII is one of the main effector peptides of the brain RAS in the control of vasopressin release; brain AngIII exerts a tonic stimulatory effect on blood pressure in a salt-dependent hypertension model.
5.3 Immune Modulation and Inflammatory Signaling
Aminopeptidase N (CD13) is a multifunctional protein recognized for its diverse roles as an enzyme, receptor, and signaling molecule—attributes that have earned it classification as a "moonlighting" protein. Its involvement in key biological processes such as inflammation, angiogenesis, cell migration, tissue invasion, and the propagation and survival of cancer cells has spurred significant interest in its potential as a therapeutic target. CD13 not only modulates development and activities of immune-related cells, but also regulates functions of inflammatory mediators; therefore, CD13 is important in the pathogenesis of various inflammatory disorders.
5.4 Tuftsin Catabolism and Immune Stimulation
Bestatin exerts a direct stimulating effect on lymphocytes via its fixation on the cell surface and an indirect effect on monocytes via aminopeptidase B inhibition of tuftsin catabolism. Tuftsin is an endogenous tetrapeptide with immunostimulatory activity; aminopeptidase-mediated tuftsin degradation is therefore relevant to innate immune tone.
6. Scientific Evidence by Area of Use
6.1 Digestive Health and Protein Digestion
Biological plausibility: The role of endogenous aminopeptidases in protein digestion is well established. AP-N is involved in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. This is a fundamental, well-accepted physiological function, not a therapeutic claim.
Exogenous enzyme supplementation — in vitro evidence: Studies using simulated digestion models have explored whether supplementing with exogenous enzyme preparations (typically multi-enzyme blends that may include aminopeptidase-type activities) can improve macronutrient digestion. Enzyme supplementation showed statistically higher release of reducing sugars in gastric digestion, and digestion of proteins and fats was also improved in the presence of the enzyme supplement. However, this particular study was conducted using an in vitro simulated digestion model (INFOGEST), not in human participants, limiting direct clinical translation.
Human clinical evidence for enzyme blends: Some clinical studies on broad-spectrum digestive enzyme supplementation have reported improvements in protein digestibility, though these typically involve multi-enzyme blends (not isolated aminopeptidase). Earlier studies have shown that co-ingestion of an exogenous enzyme blend along with plant protein increases protein digestibility; several clinical studies have demonstrated a positive impact of enzyme supplementation on protein digestion and absorption. Limitation: Most enzyme supplement clinical trials test multi-component preparations, making it impossible to attribute effects specifically to the aminopeptidase component.
6.2 Gluten-Related Disorders and Celiac Disease
Background: To date, there is no effective treatment for celiac disease (CeD), an autoimmune disease caused by gluten-containing food; celiac patients are supported by a strict gluten-free diet (GFD). One promising treatment is enzyme therapy, involving the intake of peptidases with food to digest immunogenic gluten peptides that are resistant to hydrolysis due to a high prevalence of proline and glutamine amino acids.
Role of aminopeptidase-type enzymes in gluten degradation: Complete hydrolysis of the immunodominant 33-mer gluten peptide requires an enzyme combination. Various peptidases have been isolated from lactic acid bacteria, including PepN (an aminopeptidase). Among these isolated peptidases, only the prolyl oligopeptidase (POP) hydrolyzed the Pro-Phe bond in the 33-mer alone, resulting in two peptides, one of which is still immunogenic. To achieve complete hydrolysis of the 33-mer to free amino acids, it was necessary to use a combination of peptidases including PepN (aminopeptidase), PepX, PepO, POP, PepT, PepV, and PepQ.
Clinical study — AMYNOPEP crossover trial (2024, PMC): A crossover clinical study investigated the AMYNOPEP supplement (an exopeptidase combination including aminopeptidase activity) in healthy volunteers. Researchers evaluated the effects of AMYNOPEP supplementation on 33-mer degradation in vitro and in vivo; in a cross-over clinical study, healthy volunteers with no gastrointestinal disorders were given stable isotope-labelled 33-mer peptides with and without AMYNOPEP, and degradation products were measured in blood plasma using LC-MS/MS. AMYNOPEP achieved rapid, complete amino-to-carboxyl terminal degradation of the 33-mer in vitro; in healthy volunteers, AMYNOPEP supplementation significantly increased 33-mer degradation and absorption of labelled amino acids even in the presence of competing substrates, with a 2.8-fold increase in Cmax of stable isotope-labelled amino acids in the presence of wheat gluten. The study concluded that AMYNOPEP achieved complete degradation of the 33-mer and significantly improved degradation kinetics in healthy volunteers, warranting further investigation into potential therapeutic benefits for patients with gluten-related health disorders including celiac disease. Limitation: This was conducted in healthy volunteers without celiac disease; results may not directly generalize to the disease population. Further RCTs in celiac patients are needed.
Sourdough fermentation and aminopeptidase: Sourdough Lactobacillus species (L. alimentarius, L. brevis, L. sanfranciscensis, and L. hilgardii) were selected on the basis of the hydrolytic activities of their enzymes, including aminopeptidase, which are known to digest gluten. Pilot studies showed partial improvements in celiac tolerance markers; however, evidence remains preliminary.
6.3 Hypertension and the Renin-Angiotensin System
Preclinical and mechanistic evidence: Recent evidence points to important contributions by brain angiotensin III (AngIII) and aminopeptidases A (APA) and N (APN) in sustaining hypertension. Hypertension affects one-third of the adult population; brain renin-angiotensin system (RAS) hyperactivity has been implicated in the development and maintenance of hypertension in several types of experimental and genetic hypertension animal models.
Drug development — Aminopeptidase A inhibitors: The clinical relevance of aminopeptidase in blood pressure control has driven pharmaceutical development. One review discusses novel insights from recent clinical trials with regard to interference with the renin-angiotensin system, focusing on aminopeptidase A in the brain; it raises the possibility that centrally acting aminopeptidase A inhibitors (e.g., firibastat), preventing the conversion of angiotensin II to angiotensin III in the brain, might be particularly useful in African Americans and obese patients; firibastat additionally upregulates brain ACE2, allowing the conversion of angiotensin II to its protective metabolite angiotensin-(1–7). Important distinction: This body of research pertains to the pharmacological inhibition of endogenous aminopeptidase, not to aminopeptidase enzyme supplementation per se. It represents a drug-development pipeline, not a rationale for over-the-counter aminopeptidase supplements.
6.4 Oncology — Aminopeptidase as a Therapeutic Target
Overview: The scientific literature discusses the prevalence and possible function of APN in malignant diseases, mainly solid tumors, as well as its "drugability" evaluated in preclinical in vivo models; increased expression of various hydrolytic enzymes including peptidases has been described in several types of human malignancies, especially those characterized by fast-growing and aggressive phenotypes.
Clinical evidence — Bestatin (Ubenimex): Bestatin (INN: ubenimex) is a new immunomodulating agent with low toxicity after long-term oral administration; prolongation of remission duration and survival was achieved in adult acute nonlymphocytic leukemia with bestatin immunotherapy combined with remission maintenance chemotherapy; patients with myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML) also responded to bestatin. Randomized controlled studies of bestatin immunotherapy were performed in solid tumors including malignant melanoma and carcinoma of the lung, stomach, and bladder. Limitation: Bestatin is a pharmacological inhibitor of aminopeptidase, not a supplemental aminopeptidase enzyme preparation. Randomized controlled trial data specifically on aminopeptidase enzyme supplementation in cancer are absent from the peer-reviewed literature.
Inflammatory diseases: Most of the clinical studies with CD13 enzymatic inhibitors, such as bestatin and tosedostat, were performed in cancers including leukemia, lymphomas, and carcinomas of lung, bladder, esophagus, and stomach. Inhibitors of CD13 have shown impressive anti-inflammatory effects, but none of them has yet been used for clinical therapy of human inflammatory diseases.
6.5 Flavor and Food Quality — Food Industry Applications
This is one of the best-established application areas for aminopeptidases, with robust evidence for efficacy, though it concerns food processing rather than direct human health supplementation. These enzymes are widely used in the food industry as a debittering agent as well as in the preparation of protein hydrolysates; in baking, brewing, and cheesemaking, aminopeptidases are extensively used for removing the bitterness of peptides. The application potential of aminopeptidase in the food industry includes increasing the hydrolysis efficiency and bioactivities of protein hydrolysis, debittering protein hydrolysates, improving free amino acid concentrations and bioactivity of hydrolysates, promoting cheese ripening, and enhancing flavor and nutritional value of condiments.
6.6 Peptide Synthesis and Nutraceutical Biopeptide Production
Aminopeptidases are widely used for the synthesis of biopeptides and amino acids, and are found to be more efficient than chemical synthesis. Enzymatic peptide synthesis presents a useful and helpful strategy because it can perform specified reactions under milder conditions than those used in chemical synthesis. This underlies the production of bioactive peptides (e.g., antihypertensive or collagen-derived peptides) that may then be incorporated into functional foods or supplements. The preclinical evidence for skin-active proline-rich peptides, for example, derives from fibroblast studies and has not yet been confirmed in clinical trials.
7. Body Systems and Health Areas
- Gastrointestinal system: Aminopeptidases play an important role in the metabolism of both proteins and peptides; those in the gastrointestinal tract are essential for the digestion of dietary proteins and facilitate the absorption and utilization of amino acids by cleaving them from the N-terminus of peptides.
- Cardiovascular and renal system: Brain angiotensin III (AngIII) and aminopeptidases A (APA) and N (APN) make important contributions to sustaining hypertension; novel strategies focus on limiting the binding of AngII and AngIII to the AT1 receptor by influencing the activity of APA and APN.
- Immune system: The enzyme's role in brain function and its identification as the human cluster differentiation antigen CD13 on the surface of myeloid cells highlighted its biological significance. CD13/APN is expressed on myeloid cells and is involved in immune cell development.
- Inflammatory pathways: APN/CD13 is involved in key biological processes such as inflammation, angiogenesis, cell migration, and tissue invasion.
- Oncology: Interest in CD13 as a therapeutic target extends beyond oncology to include conditions such as hypertension and rheumatoid arthritis.
- Protein metabolism (systemic): Aminopeptidases are involved in the breaking down of externally supplied peptides and are necessary for the final steps of protein turnover and replacement; they also participate in specific functions like the cleavage of N-terminal methionine from newly synthesized peptide chains (methionine aminopeptidases).
8. Dosage Forms and Reported Dosages
Aminopeptidases as dietary supplements or food enzymes exist in several commercial forms:
- Oral enzyme preparations: Multi-enzyme supplement blends in capsule or tablet form, incorporating aminopeptidase activity alongside proteases, lipases, and amylases. Activity is typically expressed in units (e.g., leucine aminopeptidase units per gram of preparation) rather than milligrams of enzyme protein.
- Food enzyme preparations (processing use): Aminopeptidase can be used in the production of flavoring substances, used as ingredients in a wide variety of final foods and drinks (e.g., bouillon cubes or powder, sauces, gravy, ready-to-consume meals, and processed cheese). The proposed application rate in flavorings production is 140–7,024 mg total organic solids (TOS) per batch, according to the FDA GRAS notification.
- Dietary exposure estimates: Based on EFSA safety evaluations, dietary exposure to leucyl aminopeptidase TOS was estimated to be up to 2.273 mg TOS/kg body weight per day in European populations (from the Aspergillus sp. strain AE-MB preparation). For the A. oryzae strain NZYM-EX preparation, dietary exposure was estimated to be up to 0.577 mg TOS/kg body weight per day in European populations. For the A. oryzae strain NZYM-BU preparation, dietary exposure to the food enzyme TOS was estimated to be up to 1.508 mg TOS/kg body weight per day in European populations.
- Bestatin (Ubenimex) — pharmaceutical (Japan): Bestatin (INN: ubenimex) has low toxicity after long-term oral administration. This is a pharmaceutical-grade aminopeptidase inhibitor, not an over-the-counter supplement, and dosages in clinical trials varied according to indication and protocol.
No standardized supplement dosage for isolated aminopeptidase has been established in clinical guidelines or official pharmacopoeial monographs. The TOS-based figures above are regulatory safety benchmarks, not therapeutic dosing recommendations.
9. Safety Considerations
9.1 Regulatory GRAS and EU Food Enzyme Status
All food enzymes currently on the EU market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list. Multiple leucyl aminopeptidase preparations from Aspergillus oryzae, Aspergillus sp., and Lichtheimia ramosa have undergone formal EFSA scientific review.
9.2 Genotoxicity
EFSA's systematic evaluations of multiple leucyl aminopeptidase preparations have consistently found favorable genotoxicity profiles. Genotoxicity tests did not indicate a safety concern for the Aspergillus sp. AE-MB preparation. Similar findings were reported for the A. oryzae NZYM-EX strain.
9.3 Systemic Toxicity
The systemic toxicity of leucyl aminopeptidase from Aspergillus sp. AE-MB was assessed by means of a repeated-dose 90-day oral toxicity study in rats; the panel identified a no-observed-adverse-effect level (NOAEL) of 183 mg TOS/kg body weight per day. For the A. oryzae NZYM-EX preparation, the Panel identified a NOAEL of 440 mg TOS/kg bw per day, the highest dose tested. For the AE-MB preparation specifically, the calculated margin of exposure for each age group was 135 (infants), 81 (toddlers), 83 (children), 109 (adolescents), 160 (adults), and 184 (the elderly), leading EFSA to conclude that the safety of the food enzyme could not be established given the derived margins of exposure. By contrast, based on the data provided, the Panel concluded that the leucyl aminopeptidase from A. oryzae NZYM-EX does not give rise to safety concerns under the intended conditions of use.
9.4 Allergenicity
EFSA has systematically assessed the allergenicity of leucyl aminopeptidase preparations. Using greater than 35% identity in a sliding window of 80 amino acids as the criterion, no match was found in the Allergen Online database or the Allergen Database for Food Safety; no allergic reactions upon dietary exposure to any leucyl aminopeptidase have been reported in the literature; the EFSA Panel considered that the results do not indicate a risk of allergic reactions upon dietary exposure. Multiple EFSA assessments have consistently concluded that the risk of allergic reactions upon dietary exposure to leucyl aminopeptidase food enzymes cannot be excluded, but the likelihood is low.
There is one notable caveat with mixed-activity preparations. Regarding enzyme preparations that co-contain oryzin (a serine protease), using greater than 35% identity in a sliding window of 80 amino acids, no match was found for leucyl aminopeptidase itself, while matches with two food allergens, three contact allergens, and 20 respiratory allergens were found for oryzin in the AllergenOnline database. This underlines the importance of distinguishing leucyl aminopeptidase-specific findings from those applicable to co-present proteins in crude preparations.
9.5 Occupational Exposure (Inhalation)
Like many industrial enzyme preparations, there is a recognized distinction between oral ingestion and occupational inhalation exposure. Among commercial enzymes used in the food industry, there were no findings of clinical relevance even in individuals with inhalation allergies to the same enzymes, and the authors concluded that ingestion of food enzymes in general is not considered to be a concern with regard to food allergy. Nonetheless, inhalation of enzyme powders in manufacturing settings carries an independent occupational sensitization risk not directly relevant to consumer dietary exposure.
9.6 Production Organism Safety
Safety evaluation of cloned DNA sequences in approved aminopeptidase preparations showed no evidence to indicate that any of the cloned DNA sequences and incorporated DNA code for or express a harmful toxic substance. The production organism used in one FDA GRAS-notified preparation, Aspergillus clavatus, carries Biosafety Level 1 classification in the ATCC database.
9.7 Drug Interactions and Contraindications
No specific drug interaction data for orally ingested aminopeptidase enzyme supplements have been identified in EFSA, FDA, NIH, or peer-reviewed sources at this time. Since aminopeptidase preparations are proteins that undergo digestion in the gastrointestinal tract, systemic pharmacokinetic interactions are considered biologically improbable under normal circumstances. However, it should be noted that, as a drug class, aminopeptidase inhibitors (e.g., bestatin/ubenimex) have been studied in clinical oncology settings and exhibit immunomodulatory effects. Several other compounds inhibiting CD13 enzymatic activity are under preclinical development, including LYP, a bestatin dimethylaminoethyl ester. These pharmacological agents are not the same as dietary aminopeptidase supplement preparations, and their interaction profiles should not be extrapolated to food enzyme products.
10. Evidence Strength Summary
- Protein digestion / gastrointestinal function (endogenous): Well-established basic science; the role of brush-border aminopeptidases in digestion is universally accepted. Evidence for orally supplemented exogenous aminopeptidase in improving digestion specifically is preliminary and mostly derived from in vitro models.
- Gluten peptide degradation: Promising early-phase clinical data in healthy volunteers (AMYNOPEP crossover study); combination enzyme products including aminopeptidase components show significant improvements in 33-mer degradation. Evidence strength is moderate-preliminary; RCTs in celiac disease patients are lacking.
- Hypertension (aminopeptidase A inhibition pathway): Strong preclinical evidence from animal models; early-phase pharmaceutical clinical trial data (firibastat). This is a drug-development pathway, not a supplement intervention. Supplementing with exogenous aminopeptidase would not be expected to replicate the effects of endogenous enzyme inhibition.
- Cancer (APN/CD13 as target): Preclinical evidence is substantial. The aminopeptidase inhibitor bestatin/ubenimex has been evaluated in randomized clinical trials in Japan for leukemia and solid tumors with positive findings. No human clinical trials exist for dietary aminopeptidase enzyme supplementation in cancer.
- Inflammatory disease: Preclinical and mechanistic evidence only; CD13 inhibitors have shown anti-inflammatory effects in animal models. No clinical trials in human inflammatory diseases with CD13 inhibitors or aminopeptidase supplements have been completed.
- Food debittering and flavor development: Well-established; robustly documented in the food science literature and supported by decades of industrial use.
References
Go back